J Neurol Surg B Skull Base 2019; 80(03): 239-243
DOI: 10.1055/s-0038-1668137
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Function-Preserving Multimodal Treatment for Jugular Foramen Meningiomas

Seiro Ito
1   Department of Neurosurgery, Chiba Rosai Hospital, Ichihara City, Chiba, Japan
,
Takashi Saegusa
1   Department of Neurosurgery, Chiba Rosai Hospital, Ichihara City, Chiba, Japan
,
Yoshinori Ozawa
1   Department of Neurosurgery, Chiba Rosai Hospital, Ichihara City, Chiba, Japan
,
Yoshinori Higuchi
2   Department of Neurosurgery, Chiba University Graduate School of Medicine, Chiba City, Chiba, Japan
,
Yasuo Iwadate
2   Department of Neurosurgery, Chiba University Graduate School of Medicine, Chiba City, Chiba, Japan
,
Toru Serizawa
3   Department of Neurosurgery, Tsukiji Neurological Clinic, Tokyo, Japan
,
Osamu Nagano
4   Department of Neurosurgery, Chiba Cerebral and Cardiovascular Center, Chiba, Japan
,
Yusuke Kageyama
5   Department of Neurosurgery, Seikei-kai Chiba Medical Center, Chiba, Japan
,
Iwao Yamakami
5   Department of Neurosurgery, Seikei-kai Chiba Medical Center, Chiba, Japan
› Author Affiliations
Further Information

Publication History

26 January 2018

30 June 2018

Publication Date:
21 August 2018 (online)

Abstract

Objectives Despite being pathologically benign, jugular foramen meningioma (JFM) may be locally aggressive and spread in three compartments. Because of the complex anatomical location, radical removal of JFM usually causes serious morbidity through lower cranial nerve (LCN) deficits. To accomplish long-standing tumor control with good functional outcomes, we report function-preserving multimodal treatment (FMT) for JFM, comprising the combination of intradural tumor removal with the preservation of LCN function and stereotactic radiosurgery (RS) for the residual tumor.

Materials This study investigated six JFM patients (five women, one man). Preoperatively, five patients showed no LCN sign.

Results All patients underwent function-preserving retrosigmoid intradural tumor removal, and no patient developed new LCN deficit. Three patients underwent RS for the residual tumor at 8 to 12 months after surgery. After RS, all three tumors were controlled. No patients showed tumor recurrence or new LCN deficits in the follow-up period (2 months to 8 years).

Conclusion FMT for JFMs can accomplish long-standing tumor control with excellent functional outcomes.